Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TMEM97 | Q5BJF2 | 5/20 | 0.57 |
| ▸ | SIGMAR1 | Q99720 | 5/20 | 0.57 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.52 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.52 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.52 |
| ▸ | CXCR3 | P49682 | 1/20 | 0.46 |
| ▸ | PTGDR2 | Q9Y5Y4 | 11/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29984651 | 0.87 | TMEM97 (0.56) | TMEM97SIGMAR1HDAC1HDAC6HDAC10 | |
| SCHEMBL21996420 | 0.87 | TMEM97 (0.56) | TMEM97SIGMAR1HDAC1HDAC6HDAC10 | |
| SCHEMBL22054667 | 0.83 | ENPP2 (0.44) | CXCR3PTGDR2KMT2A | |
| SCHEMBL22055341 | 0.78 | HDAC1 (0.46) | TMEM97SIGMAR1HDAC1HDAC6HDAC10 | |
| SCHEMBL22054358 | 0.75 | ADRA2A (0.61) | SIGMAR1HDAC1HDAC6 | |
| SCHEMBL23949707 | 0.74 | TMEM97 (0.57) | TMEM97SIGMAR1HDAC1HDAC6PTGDR2 | |
| SCHEMBL6485348 | 0.74 | MEN1 (0.49) | TMEM97SIGMAR1HDAC1HDAC6PTGDR2 | |
| SCHEMBL6483674 | 0.74 | SMN1; SMN2 (0.48) | TMEM97SIGMAR1HDAC1HDAC6HDAC10 | |
| SCHEMBL13011574 | 0.74 | HDAC1 (0.61) | TMEM97SIGMAR1HDAC1HDAC6HDAC10 | |
| SCHEMBL22054663 | 0.73 | PTGDR2 (0.57) | TMEM97SIGMAR1HDAC1HDAC6HDAC10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220024924-A1 | SOLID STATE FORMS OF LUMATEPERONE SALTS AND PROCESSES FOR PREPARATION OF LUMATEPERONE AND SALTS THEREOF | ASSIA CHEMICAL INDUSTRIES LTD. (IL) | 2022-01-27 | — | — | US | disclosed |
| EP-3887374-A2 | SOLID STATE FORMS OF LUMATEPERONE SALTS AND PROCESSES FOR PREPARATION OF LUMATEPERONE AND SALTS THEREOF | Teva Pharmaceuticals International GmbH (CH) | 2021-10-06 | — | — | EP | disclosed |
| WO-2020112941-A2 | SOLID STATE FORMS OF LUMATEPERONE SALTS AND PROCESSES FOR PREPARATION OF LUMATEPERONE AND SALTS THEREOF | TEVA CZECH INDUSTRIES S.R.O (CZ) | 2020-06-04 | — | — | WO | disclosed |
| WO-2020112941-A2 | SOLID STATE FORMS OF LUMATEPERONE SALTS AND PROCESSES FOR PREPARATION OF LUMATEPERONE AND SALTS THEREOF | TEVA CZECH INDUSTRIES S.R.O (CZ) | 2020-06-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220024924-A1 | SOLID STATE FORMS OF LUMATEPERONE SALTS AND PROCESSES FOR PREPARATION OF LUMATEPERONE AND SALTS THEREOF | RALA, TACR1, SRM | TMEM97 302/4885SIGMAR1 691/4885HDAC1 4810/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.